Platform & Strategies


HomePlatform & StrategiesPublications


Publications(Pipeline, Jernal, Date, Title, Link, PDF)
Pipeline Jernal Date Title Link PDF
ABL001 mAbs 2016 Simultaneous blockade of VEGF and Dll4 by HD105, a bispecific antibody, inhibits tumor progression and angiogenesis 링크정보 아이콘 PDF 아이콘
BMB Reports 2020 Synergistic antitumor activity of a DLL4/VEGF bispecific therapeutic antibody in combination with irinotecan in gastric cancer 링크정보 아이콘 PDF 아이콘
Int J Mol Sci 2020 ABL001, a bispecific antibody targeting VEGF and DLL4, with chemotherapy, synergistically inhibits tumor progression in xenograft models 링크정보 아이콘 PDF 아이콘
4-1BB Platform Science Advances 2021 B7-H3×4-1BB bispecific antibody augments antitumor immunity by enhancing terminally differentiated CD8+tumor-infiltrating lymphocytes 링크정보 아이콘 PDF 아이콘
ADC (Nterm) mAbs 2021 N-terminal selective conjugation method widens the therapeutic window of antibody–drug conjugates by improving tolerability and stability 링크정보 아이콘 PDF 아이콘
ABL503 JITC 2021 Novel anti-4-1BB×PD-L1 bispecific antibody augments anti-tumor immunity through tumor-directed T-cell activation and checkpoint blockade 링크정보 아이콘 PDF 아이콘


Posters(Pipeline, Name, Title, PDF)
Pipeline Name Title PDF
ABL001 PEGS 2017 Preclinical development of an anti-cancer bispecific antibody targeting VEGF and DLL4, ABL001 PDF 아이콘
ASCO 2019 Phase 1a study results investigating the safety and preliminary efficacy of ABL001 (NOV1501), a bispecific antibody targeting VEGF and DLL4 in metastatic gastrointesinal (GI) cancer PDF 아이콘
PEPTALK 2020 Summary of phase 1a dose escalation clinical study data for dual angiogenic bispecific antibody targeting VEGF and DLL4 (ABL001/NOV1501/TR009) in patients with previously treated solid tumors PDF 아이콘
ABL105 AACR 2020 A novel HER2/4-1BB bispecific antibody, YH32367 (ABL105) shows potent anti-tumor effect through tumor-directed T cell activation PDF 아이콘
4-1BB Platform AACR 2020 B7-H3-targeted 4-1BB activation potentiates CD8 T cell-dependent antitumor immunity without systemic toxicity PDF 아이콘
AACR 2021 A novel anti-CD137 antibody recognizing the membrane-proximal CD137 domain elicits potent anti-tumor T cell activity in a bispecific antibody format PDF 아이콘
ABL503 PEGS Boston 2019 The PD-L1x4-1BB Bispecific Antibody ABL503 Shows Potent Anti-Tumor Effect through Tumor-Directed T Cell Activation PDF 아이콘
ABL111 AACR 2020 Claudin 18.2 - 4-1BB bispecific antibody induced potent tumor inhibition through tumor-specific 4-1BB activation PDF 아이콘
ABL501 AACR 2021 ABL501 (PD-L1xLAG-3), a bispecific antibody promotes enhanced human T cell activation through targeting simultaneously two immune checkpoint inhibitors, LAG-3 and PD-L1 PDF 아이콘
ABL301 Keystone 2019 ABL301, BBB-Crossing Trojan Horse Bispecific Antibody Specifically Targeting Aggregated a-synuclein for the Treatment of Parkinson’s Disease (PD) PDF 아이콘
AD/PD 2020 A novel blood-brain barrier-crossing bispecific antibody targeting aggregated α-synuclein(ABL301) attenuates α-synuclein propagation and ameliorates synucleinopathy PDF 아이콘
AD/PD 2021 ABL301 Has Superior Efficacy on Synucleinopathies and Sustained CNS Exposure via Grabody B, an IGF1R-targeting BBB Shuttle PDF 아이콘